The CEO Roundtable on Cancer is a 501(c)(3), non-profit corporation, comprised of chief executives from more than thirty major American companies representing diverse industries, from nonprofit organizations that are committed to fighting cancer, and from several National Cancer Institute-designated cancer centers. It is supported in full by annual contributions from its membership. The mission of the CEO Roundtable is make continual progress toward the elimination of cancer as a personal disease and as a public health problem. Members of the CEO Roundtable collaboratively work to develop and implement initiatives that reduce the risk of cancer, enable early diagnosis, facilitate better access to best-available treatments, and hasten the discovery of novel and more effective diagnostic tools and anti-cancer therapies.
The CEO Roundtable on Cancer was founded in 2001 by Robert A. Ingram, then the CEO of Glaxo Wellcome (now GlaxoSmithKline) at the request of former President George H.W. Bush. Mr. Ingram was asked to convene and chair the CEO Roundtable on Cancer in support of an historic initiative known as C-Change. Read The History for additional information.
The CEO Roundtable on Cancer currently has two Task Forces: The CEO Cancer Gold Standard (“Gold Standard”) Task Force and the Life Sciences Consortium (“LSC”) Task Force. The CEO Cancer Gold Standard™ created by the Member CEOs in 2004, is a comprehensive, workplace-based initiative that encourages state-of-the-science prevention, early diagnosis and quality treatment. The Life Sciences Consortium (LSC) was formed in 2005 as a means of bringing together leading oncology pharmaceutical/biotechnology companies to build collaboration in cancer drug development. The goal of these collaborations is a transformation in research and development that will effectively deliver new agents to prevent and treat cancer to people who need them and fulfill the promise of our emerging understanding of cancer biology. This collaboration focuses on exploring and solving issues common to all cancer companies engaged in drug discovery and development that cannot be solved by any company alone.
Members of the CEO Roundtable on Cancer are invited by the Chairman, CEO Roundtable on Cancer, and are asked to make an annual contribution in support of the CEO Roundtable initiatives.
No, as a non-profit, vendor-neutral organization, The CEO Roundtable on Cancer does not formally endorse any product, service or company. Please review the Vendor Endorsement Policy for additional information.